Assessment of readability of gynecologic cancer clinical trials literature at National Cancer Institute–designated Comprehensive Cancer Centers
Julia Chalif(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Laura Chambers(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), John L. Hays(The Ohio State University), Wafa Khadraoui(University of Miami), Larry J. Copeland(Gynecologic Oncology Group), Roberto Vargas(Gynecologic Oncology Group), David M. O’Malley(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 1
Related Papers
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
|Journal of the National Comprehensive Cancer Network|2019|332
Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
|Molecular Cancer Therapeutics|2020|138
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
|Journal of Clinical Oncology|2023|100
Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
|Molecular Cancer Therapeutics|2017|93